Patent directory · USPTO A61K / A61P
Patents matching “Phio Pharmaceuticals Corp.”
20 pharma patents match "Phio Pharmaceuticals Corp." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 20 pharmaceutical patents matching "Phio Pharmaceuticals Corp." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 11926828
Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
granted -
US 11584933
RNA interference in ocular indications
granted -
US 11396654
Neutral nanotransporters
granted -
US 11279934
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
granted -
US 11254940
Inhibition of MAP4K4 through RNAi
granted -
US 11118178
Reduced size self-delivering RNAI compounds
granted -
US 11021707
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
granted -
US 11001845
Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
granted -
US 10934550
Immunotherapy of cancer
granted -
US 10913948
RNA interference in dermal and fibrotic indications
granted -
US 10900039
Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
granted -
US 10876119
Reduced size self-delivering RNAI compounds
granted -
US 10815485
RNA interference in skin indications
granted -
US 10808247
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
granted -
US 10774330
Reduced size self-delivering RNAI compounds
granted -
US 10662430
RNA interference in ocular indications
granted -
US 10633654
Modified RNAi polynucleotides and uses thereof
granted -
US 10300027
Effective sensitizing dose of a gelled immunomodulating topical composition
granted -
US 10240149
Reduced size self-delivering RNAi compounds
granted -
US 10184124
RNA interference in ocular indications
granted